Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

A Randomized, Open-Label, Phase III Study of Taxane Based Chemotherapy With Lapatinib or Trastuzumab as First-Line Therapy for Women With HER2/Neu Positive Metastatic Breast Cancer

ClinicalTrials.gov Identifier: NCT00667251

Novartis Reference Number: 108919

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

RATIONALE: HER2/neu is a receptor (protein) which is found in unusually high amounts in approximately 1 in 5 cancer patients. Scientific evidence suggests that having high amounts of the HER2/neu receptor is important for breast cancer to grow and spread. Women with previously untreated metastatic breast cancer (breast cancer that has spread to other organs) and with high levels of the HER2/neu receptor receive as their usual treatment chemotherapy with one of the approved chemotherapy drugs paclitaxel or docetaxel (called "taxanes") together with another approved drug called "trastuzumab". Chemotherapy drugs, such as paclitaxel and docetaxel, work either by killing tumour cells or by stopping them from dividing. Trastuzumab is an antibody that is given through a vein in the arm and it works by specifically "targeting" the HER2/neu i.e. it attaches to it and "turns it off". Although some of the patients who receive this taxane plus trastuzumab treatment feel better for some months, the cancer usually starts to grow again. Lapatinib is a new drug. Like trastuzumab, it also works by specifically "targeting" the HER2/neu receptor, but it does so in a different way. Lapatinib is not an antibody. It is a pill that is taken daily by mouth. Because lapatinib works in a different way than trastuzumab, it may be worse, as good as or better than trastuzumab in keeping metastatic HER/neu positive cancer from growing. However, this is not known.

Purpose: This randomized Phase III trial is comparing chemotherapy (a taxane) given together with lapatinib with chemotherapy (a taxane) given together with trastuzumab in women with HER2/neu positive breast cancer.

Condition 
Breast Cancer
Phase 
Phase 3
Overall status 
Active, not recruiting
Enrollment count 
649 participants
Start date 
Oct 07, 2008
Completion date 
Dec 31, 2020
Gender 
Female
Age(s)
18 Years and older (Adult, Older Adult)

Interventions

Biological
trastuzumab
IV q weekly (loading dose 4mg/kg; subsequent doses 2mg/kg) or IV q 3 weekly (loading dose 8mg/kg, subsequent doses 6mg/kg).
Drug
docetaxel
75mg/m2 IV q 3 weekly, day 1 of a 3 week cycle for 8 cycles plus G-CSF (when given together with lapatinib).
Drug
lapatinib ditosylate
1250 mg po daily (while given with taxane). 1500mg PO daily (when given alone after taxane completion).
Drug
paclitaxel
80mg/m2 IV q weekly days 1, 8 and 15 of a 4-week cycle for 6 cycles.

Eligibility Criteria

DISEASE CHARACTERISTICS:

Histologically confirmed adenocarcinoma of the breast
Metastatic (stage IV) disease at primary diagnosis or at relapse after curative intent therapy

Local or central laboratory confirmedHER2/neu* overexpressing and/or amplified disease in the invasive component of the primary or metastatic lesion as defined by the following:

3+ overexpression (in > 30% of invasive tumor cells) by immunohistochemistry (IHC)
2+ or 3+ overexpression (in ≤ 30% of invasive tumor cells) by IHC AND demonstrates HER2/neu gene amplification by fluorescence in situ hybridization (FISH) or chromogenic in situ hybridization (CISH)
HER2/neu gene amplification by FISH/CISH (> 6 HER2/neu gene copies per nucleus, or a FISH/CISH ratio [HER2 gene copies to chromosome 17 signals] of ≥ 2.2) NOTE: *Patients with a negative or equivocal overall result (FISH/CISH ratio of < 2.2, ≤ 6.0 HER2/neu gene copies per nucleus, or staining scores of 0, 1+, 2+, or 3+ [in ≤ 30% of neoplastic cells] by IHC) are not eligible
Formalin-fixed paraffin-embedded tumor specimen available
No CNS metastases (including leptomeningeal involvement)
Hormone receptor status not specified

PATIENT CHARACTERISTICS:

Menopausal status not specified
ECOG performance status 0-2
Life expectancy > 6 months
Absolute granulocyte count > 1,500/mm³
Platelet count > 75,000/mm³
Hemoglobin > 10 g/dL
Serum creatinine ≤ 2.0 times upper limit of normal (ULN)
Total bilirubin ≤ 1.5 times ULN (< 3 times ULN for patients with Gilbert's disease)
AST and/or ALT ≤ 2.5 times ULN (< 5 times ULN for patients planning to receive paclitaxel-based therapy)
LVEF ≥ 50% by MUGA or ECHO
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
Must be accessible for study treatment and follow-up
No history of other malignancies, except adequately treated ductal carcinoma in situ or lobular carcinoma in situ, adequately treated nonmelanoma skin cancer, curatively treated carcinoma in situ of the cervix, or other curatively treated solid tumor (non-breast) with no evidence of disease for ≥ 5 years

No serious cardiac illness or condition including, but not limited to, any of the following:

History of documented congestive heart failure
Systolic dysfunction (LVEF < 50%)
High-risk uncontrolled arrhythmias (i.e., ventricular tachycardia, high-grade atrioventricular block, or supraventricular arrhythmias that are not adequately rate-controlled)
Unstable angina pectoris requiring anti-anginal medication
Clinically significant valvular heart disease
Evidence of transmural infarction on ECG
Inadequately controlled hypertension (i.e., systolic blood pressure [BP] > 180 mm Hg or diastolic BP > 100 mm Hg)
New York Heart Association class III-IV functional status

No serious illness or medical condition that would not allow the patient to be managed according to the protocol including, but not limited to, any of the following:

History of significant neurologic or psychiatric disorder that would impair the ability to obtain informed consent or limit compliance with study requirements
Active uncontrolled infection
Serious or nonhealing wound, ulcer, or bone fracture
No peripheral neuropathy ≥ grade 2

No gastrointestinal (GI) tract disease resulting in an inability to take oral medication including, but not limited to, any of the following:

Malabsorption syndrome
Requirement for IV alimentation
Uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative colitis)

No history of allergic or hypersensitivity reactions to any study drug or their excipients or to compounds with similar chemical composition to any of the study drugs

Prior allergic reactions to taxanes are allowed provided they were adequately treated and, according to the treating physician, would not prohibit further treatment with taxanes

PRIOR CONCURRENT THERAPY:

Recovered from all prior therapy
No prior chemotherapy, immunotherapy, biological therapy, or anti-HER2/neu-targeted therapy for recurrent or metastatic breast cancer
At least 12 months since prior chemotherapeutic agents, including taxanes, in the neoadjuvant or adjuvant setting
At least 12 months since prior anti-HER2/neu-targeted therapy in the neoadjuvant or adjuvant setting
Prior treatment with endocrine therapy in the neoadjuvant, adjuvant, or metastatic setting allowed

At least 2 weeks since prior radiotherapy in the adjuvant or metastatic setting

Prior radiotherapy to a solitary metastatic lesion allowed provided there is documented disease progression after completion of radiotherapy
More than 30 days (or 5 half-lives) since prior investigational drugs
At least 7 days since prior and no concurrent CYP3A4 inhibitors (6 months for amiodarone)
At least 14 days since prior and no concurrent CYP3A4 inducers
No prior surgical procedures affecting absorption (e.g., resection of stomach or small bowel)
No concurrent palliative radiotherapy
No other concurrent anticancer treatment
No other concurrent investigational drugs for breast cancer

Study Locations

United States
Novartis Investigative Site
-
Anchorage, 99508
Alaska
United States
Novartis Investigative Site
-
Tucson, 85715
Arizona
United States
Novartis Investigative Site
-
Hot Springs, 71913
Arkansas
United States
Novartis Investigative Site
-
Berkeley, 94704
California
United States
Novartis Investigative Site
-
Highland, 92346
California
United States
Novartis Investigative Site
-
Montebello, 90640
California
United States
Novartis Investigative Site
-
Colorado Springs, 80907
Colorado
United States
Novartis Investigative Site
-
Denver, 80204
Colorado
United States
Novartis Investigative Site
-
Greenwich, 06830
Connecticut
United States
Novartis Investigative Site
-
Southington, 06489
Connecticut
United States
Novartis Investigative Site
-
Stamford, 06902-3628
Connecticut
United States
Novartis Investigative Site
-
Trumbull, 06611
Connecticut
United States
Novartis Investigative Site
-
Waterbury, 06708
Connecticut
United States
Novartis Investigative Site
-
Kissimmee, 34741
Florida
United States
Novartis Investigative Site
-
Loxahatchee Groves, 33470
Florida
United States
Novartis Investigative Site
-
New Port Richey, 34655
Florida
United States
Novartis Investigative Site
-
Augusta, 30901
Georgia
United States
Novartis Investigative Site
-
Lawrenceville, 30046
Georgia
United States
Novartis Investigative Site
-
Savannah, 31405
Georgia
United States
Novartis Investigative Site
-
Post Falls, 83854
Idaho
United States
Novartis Investigative Site
-
Chicago, 60657
Illinois
United States
Novartis Investigative Site
-
Oak Lawn, 60453
Illinois
United States
Novartis Investigative Site
-
Evansville, 47713
Indiana
United States
Novartis Investigative Site
-
Goshen, 46526
Indiana
United States
Novartis Investigative Site
-
Indianapolis, 46237
Indiana
United States
Novartis Investigative Site
-
Munster, 46321
Indiana
United States
Novartis Investigative Site
-
New Albany, 47150
Indiana
United States
Novartis Investigative Site
-
Towson, 21204
Maryland
United States
Novartis Investigative Site
-
Wheaton, 20902
Maryland
United States
Novartis Investigative Site
-
Bozeman, 59715
Montana
United States
Novartis Investigative Site
-
Grand Island, 68803
Nebraska
United States
Novartis Investigative Site
-
Kearney, 68845
Nebraska
United States
Novartis Investigative Site
-
Kearney, 68847
Nebraska
United States
Novartis Investigative Site
-
Denville, 07834
New Jersey
United States
Novartis Investigative Site
-
Parsippany, 07054
New Jersey
United States
Novartis Investigative Site
-
Cooperstown, 13326
New York
United States
Novartis Investigative Site
-
Greensboro, 27403
North Carolina
United States
Novartis Investigative Site
-
Canton, 44718
Ohio
United States
Novartis Investigative Site
-
Wooster, 44691
Ohio
United States
Novartis Investigative Site
-
Portland, 97227
Oregon
United States
Novartis Investigative Site
-
Pittsburgh, 15212-4772
Pennsylvania
United States
Novartis Investigative Site
-
Columbia, 29210
South Carolina
United States
Novartis Investigative Site
-
Memphis, 38120
Tennessee
United States
Novartis Investigative Site
-
Chesapeake, 23320
Virginia
United States
Novartis Investigative Site
-
Salem, 24153
Virginia
United States
Novartis Investigative Site
-
Bellevue, 98004
Washington
United States
Novartis Investigative Site
-
Kirkland, 98034
Washington
United States
Novartis Investigative Site
-
Mount Vernon, 98273
Washington
United States
Novartis Investigative Site
-
Seattle, 98109
Washington
United States
Novartis Investigative Site
-
Sequim, 98382
Washington
United States
Novartis Investigative Site
-
Tacoma, 98405
Washington
United States
Novartis Investigative Site
-
Wenatchee, 98801
Washington
United States
Novartis Investigative Site
-
Milwaukee, 53226
Wisconsin
United States
Argentina
Novartis Investigative Site
-
Capital Federal, C1405CUB
Buenos Aires
Argentina
Novartis Investigative Site
-
Capital Federal, C1426ANZ
Buenos Aires
Argentina
Novartis Investigative Site
-
Ciudad Autonoma de Buenos Aires, C1280AEB
Buenos Aires
Argentina
Novartis Investigative Site
-
La Plata, B1920CMK
Buenos Aires
Argentina
Novartis Investigative Site
-
Cipolletti, R8324EMB
Río Negro
Argentina
Novartis Investigative Site
-
Viedma, R8500ACE
Río Negro
Argentina
Novartis Investigative Site
-
Rosario, S2000KZE
Santa Fe
Argentina
Novartis Investigative Site
-
Santa Fe, 3000
-
Argentina
Novartis Investigative Site
-
Tucuman, 4000
-
Argentina
Australia
Novartis Investigative Site
-
Garran, 2606
Australian Capital Territory
Australia
Novartis Investigative Site
-
Liverpool, 2170
New South Wales
Australia
Novartis Investigative Site
-
North Sydney, 2060
New South Wales
Australia
Novartis Investigative Site
-
Tweed Heads, 2485
New South Wales
Australia
Novartis Investigative Site
-
Woolloongabba, 4102
Queensland
Australia
Novartis Investigative Site
-
Adelaide, 5000
South Australia
Australia
Novartis Investigative Site
-
Bedford Park, 5042
South Australia
Australia
Novartis Investigative Site
-
Kurralta Park, 5037
South Australia
Australia
Novartis Investigative Site
-
Hobart, 7000
Tasmania
Australia
Novartis Investigative Site
-
Box Hill, 3128
Victoria
Australia
Novartis Investigative Site
-
Fitzroy, 3065
Victoria
Australia
Novartis Investigative Site
-
Wodonga, 3690
Victoria
Australia
Novartis Investigative Site
-
Subiaco, 6008
Western Australia
Australia
Belgium
Novartis Investigative Site
-
Gent, 9000
-
Belgium
Novartis Investigative Site
-
Jette, 1090
-
Belgium
Novartis Investigative Site
-
Liege, 4000
-
Belgium
Novartis Investigative Site
-
Namur, 5000
-
Belgium
Canada
Novartis Investigative Site
-
Edmonton, T6G 1Z2
Alberta
Canada
Novartis Investigative Site
-
Kelowna, V1Y 5L3
British Columbia
Canada
Novartis Investigative Site
-
Surrey, V3V 1Z2
British Columbia
Canada
Novartis Investigative Site
-
Vancouver, V5Z 4E6
British Columbia
Canada
Novartis Investigative Site
-
Victoria, V8R 6V5
British Columbia
Canada
Novartis Investigative Site
-
Winnipeg, R3E 0V9
Manitoba
Canada
Novartis Investigative Site
-
Moncton, E1C 6Z8
New Brunswick
Canada
Novartis Investigative Site
-
Saint John, E2L 4L2
New Brunswick
Canada
Novartis Investigative Site
-
Barrie, L4M 6M2
Ontario
Canada
Novartis Investigative Site
-
Hamilton, L8V 5C2
Ontario
Canada
Novartis Investigative Site
-
Kingston, K7L 5P9
Ontario
Canada
Novartis Investigative Site
-
London, N6A 4L6
Ontario
Canada
Novartis Investigative Site
-
Newmarket, L3Y 2P9
Ontario
Canada
Novartis Investigative Site
-
Ottawa, K1H 8L6
Ontario
Canada
Novartis Investigative Site
-
Sault Ste. Marie, P6B 0A8
Ontario
Canada
Novartis Investigative Site
-
St Catharines, L2R 7C6
Ontario
Canada
Novartis Investigative Site
-
Sudbury, P3E 5J1
Ontario
Canada
Novartis Investigative Site
-
Thunder Bay, P7B 6V4
Ontario
Canada
Novartis Investigative Site
-
Charlottetown, C1A 8T5
Prince Edward Island
Canada
Novartis Investigative Site
-
Montreal, H1T 2M4
Quebec
Canada
Novartis Investigative Site
-
Montreal, H2L 4M1
Quebec
Canada
Novartis Investigative Site
-
Montreal, H2W 1S6
Quebec
Canada
Novartis Investigative Site
-
Regina, S4T 7T1
Saskatchewan
Canada
Novartis Investigative Site
-
Saskatoon, S7N 4H4
Saskatchewan
Canada
Novartis Investigative Site
-
Quebec, G1S 4L8
-
Canada
France
Novartis Investigative Site
-
Angers, 49033
-
France
Novartis Investigative Site
-
Bordeaux, 33075
-
France
Novartis Investigative Site
-
Bordeaux, 33077
-
France
Novartis Investigative Site
-
Caen Cedex 05, 14076
-
France
Novartis Investigative Site
-
Marseille cedex 9, 13273
-
France
Novartis Investigative Site
-
Metz-Tessy, 74370
-
France
Novartis Investigative Site
-
Nantes cedex, 44202
-
France
Novartis Investigative Site
-
Paris, 75014
-
France
Novartis Investigative Site
-
Strasbourg, 67085
-
France
Germany
Novartis Investigative Site
-
Heidelberg, 69115
Baden-Wuerttemberg
Germany
Novartis Investigative Site
-
Stuttgart, 70190
Baden-Wuerttemberg
Germany
Novartis Investigative Site
-
Coburg, 96450
Bayern
Germany
Novartis Investigative Site
-
Eggenfelden, 84307
Bayern
Germany
Novartis Investigative Site
-
Fuerth, 90766
Bayern
Germany
Novartis Investigative Site
-
Regensburg, 93049
Bayern
Germany
Novartis Investigative Site
-
Rosenheim, 83022
Bayern
Germany
Novartis Investigative Site
-
Weiden, 92637
Bayern
Germany
Novartis Investigative Site
-
Fuerstenwalde, 15517
Brandenburg
Germany
Novartis Investigative Site
-
Frankfurt, 60596
Hessen
Germany
Novartis Investigative Site
-
Fulda, 36043
Hessen
Germany
Novartis Investigative Site
-
Lich, 35423
Hessen
Germany
Novartis Investigative Site
-
Goslar, 38642
Niedersachsen
Germany
Novartis Investigative Site
-
Hannover, 30559
Niedersachsen
Germany
Novartis Investigative Site
-
Leer, 26789
Niedersachsen
Germany
Novartis Investigative Site
-
Bielefeld, 33611
Nordrhein-Westfalen
Germany
Novartis Investigative Site
-
Bonn, 53113
Nordrhein-Westfalen
Germany
Novartis Investigative Site
-
Coesfeld, 48653
Nordrhein-Westfalen
Germany
Novartis Investigative Site
-
Essen, 45122
Nordrhein-Westfalen
Germany
Novartis Investigative Site
-
Koeln, 51067
Nordrhein-Westfalen
Germany
Novartis Investigative Site
-
Porta Westfalica, 32457
Nordrhein-Westfalen
Germany
Novartis Investigative Site
-
Troisdorf, 53840
Nordrhein-Westfalen
Germany
Novartis Investigative Site
-
Velbert, 42551
Nordrhein-Westfalen
Germany
Novartis Investigative Site
-
Witten, 58452
Nordrhein-Westfalen
Germany
Novartis Investigative Site
-
Koblenz, 56068
Rheinland-Pfalz
Germany
Novartis Investigative Site
-
Saarbruecken, 66113
Saarland
Germany
Novartis Investigative Site
-
Halle, 06120
Sachsen-Anhalt
Germany
Novartis Investigative Site
-
Dresden, 01127
Sachsen
Germany
Novartis Investigative Site
-
Luebeck, 23538
Schleswig-Holstein
Germany
Novartis Investigative Site
-
Berlin, 10117
-
Germany
Novartis Investigative Site
-
Berlin, 10367
-
Germany
Novartis Investigative Site
-
Brandenburg, 14770
-
Germany
Novartis Investigative Site
-
Hamburg, 20095
-
Germany
Novartis Investigative Site
-
Hamburg, 22081
-
Germany
Novartis Investigative Site
-
Hamburg, 22767
-
Germany
India
Novartis Investigative Site
-
Bangalore, 560038
-
India
Novartis Investigative Site
-
Nagpur, 440010
-
India
Novartis Investigative Site
-
Pune, 411001
-
India
Israel
Novartis Investigative Site
-
Beer-Sheva, 84101
-
Israel
Novartis Investigative Site
-
Holon, 58100
-
Israel
Novartis Investigative Site
-
Petah-Tikva, 49100
-
Israel
Novartis Investigative Site
-
Poriya, 15208
-
Israel
Novartis Investigative Site
-
Ramat Gan, 52621
-
Israel
Italy
Novartis Investigative Site
-
Aviano (pn), 33081
Friuli-Venezia-Giulia
Italy
Novartis Investigative Site
-
Roma, 00189
Lazio
Italy
Novartis Investigative Site
-
Sora (FR), 03039
Lazio
Italy
Novartis Investigative Site
-
Genova, 16132
Liguria
Italy
Novartis Investigative Site
-
Lecce, 73100
Puglia
Italy
Novartis Investigative Site
-
Sassari, 07100
Sardegna
Italy
Novartis Investigative Site
-
Prato (PO), 59100
Toscana
Italy
Novartis Investigative Site
-
Chieti, 66100
-
Italy
Japan
Novartis Investigative Site
-
Aichi, 464-8681
-
Japan
Novartis Investigative Site
-
Chiba, 277-8577
-
Japan
Novartis Investigative Site
-
Ehime, 791-0280
-
Japan
Novartis Investigative Site
-
Kagoshima, 892-0833
-
Japan
Novartis Investigative Site
-
Kanagawa, 241-8515
-
Japan
Novartis Investigative Site
-
Osaka, 540-0006
-
Japan
Novartis Investigative Site
-
Osaka, 565-0871
-
Japan
Novartis Investigative Site
-
Saitama, 350-1298
-
Japan
Novartis Investigative Site
-
Saitama, 362-0806
-
Japan
Novartis Investigative Site
-
Shizuoka, 411-8777
-
Japan
Novartis Investigative Site
-
Tokyo, 104-8560
-
Japan
Novartis Investigative Site
-
Tokyo, 113-8677
-
Japan
Korea, Republic of
Novartis Investigative Site
-
Gyeonggi-do, 10408
-
Korea, Republic of
Novartis Investigative Site
-
Gyeonggi-do, 410-769
-
Korea, Republic of
Novartis Investigative Site
-
Seoul, 03722
-
Korea, Republic of
Novartis Investigative Site
-
Seoul, 110-744
-
Korea, Republic of
Novartis Investigative Site
-
Seoul, 120-752
-
Korea, Republic of
Novartis Investigative Site
-
Songpa-gu, Seoul, 138-736
-
Korea, Republic of
Mexico
Novartis Investigative Site
-
Cuernavaca, 62450
Morelos
Mexico
Novartis Investigative Site
-
Ciudad Obregon, 85000
Sonora
Mexico
Novartis Investigative Site
-
Mexico City, CP 14080
-
Mexico
Netherlands
Novartis Investigative Site
-
Amsterdam, 1091 AC
-
Netherlands
Novartis Investigative Site
-
Delft, 2625 AD
-
Netherlands
Novartis Investigative Site
-
Dordrecht, 3318 AT
-
Netherlands
Novartis Investigative Site
-
Maastricht, 6229 HX
-
Netherlands
Poland
Novartis Investigative Site
-
Gdansk, 80-219
-
Poland
Novartis Investigative Site
-
Lodz, 93-509
-
Poland
Novartis Investigative Site
-
Olsztyn, 10-226
-
Poland
Novartis Investigative Site
-
Olsztyn, 10-513
-
Poland
Novartis Investigative Site
-
Plock, 09-400
-
Poland
Novartis Investigative Site
-
Rzeszow, 35-021
-
Poland
Novartis Investigative Site
-
Warszawa, 02-781
-
Poland
Novartis Investigative Site
-
Warszawa, 04-125
-
Poland
Russian Federation
Novartis Investigative Site
-
Arkhangelsk, 163045
-
Russian Federation
Novartis Investigative Site
-
Ivanovo, 153013
-
Russian Federation
Novartis Investigative Site
-
Kazan, 420029
-
Russian Federation
Novartis Investigative Site
-
Kirov, 610021
-
Russian Federation
Novartis Investigative Site
-
Lipetsk, 398005
-
Russian Federation
Novartis Investigative Site
-
Moscow, 115 478
-
Russian Federation
Novartis Investigative Site
-
Ryazan, 390011
-
Russian Federation
Novartis Investigative Site
-
St. Petersburg, 197022
-
Russian Federation
Novartis Investigative Site
-
St. Petersburg, 197758
-
Russian Federation
Novartis Investigative Site
-
Stavropol, 355047
-
Russian Federation
Novartis Investigative Site
-
Ufa,, 450054
-
Russian Federation
Novartis Investigative Site
-
Ufa, 450054
-
Russian Federation
Spain
Novartis Investigative Site
-
Alcorcon, 28922
-
Spain
Novartis Investigative Site
-
Alicante, 03010
-
Spain
Novartis Investigative Site
-
Badalona, 08916
-
Spain
Novartis Investigative Site
-
Barcelona, 08036
-
Spain
Novartis Investigative Site
-
Elche, 03202
-
Spain
Novartis Investigative Site
-
Girona, 17007
-
Spain
Novartis Investigative Site
-
Jaen, 23007
-
Spain
Novartis Investigative Site
-
La Coruna, 15009
-
Spain
Novartis Investigative Site
-
Lugo, 27003
-
Spain
Novartis Investigative Site
-
Madrid, 28007
-
Spain
Novartis Investigative Site
-
Madrid, 28034
-
Spain
Novartis Investigative Site
-
Madrid, 28040
-
Spain
Novartis Investigative Site
-
Majadahonda (Madrid), 28222
-
Spain
Novartis Investigative Site
-
Pozuelo De Alarcon (Madrid), 28223
-
Spain
Novartis Investigative Site
-
Sevilla, 41013
-
Spain
Novartis Investigative Site
-
Valencia, 46009
-
Spain
Taiwan
Novartis Investigative Site
-
Changhua, 500
-
Taiwan
Novartis Investigative Site
-
Taichung, 404
-
Taiwan
Novartis Investigative Site
-
Tainan County, 736
-
Taiwan
Novartis Investigative Site
-
Taipei, 100
-
Taiwan
Novartis Investigative Site
-
Taipei, 112
-
Taiwan
Thailand
Novartis Investigative Site
-
Bangkok, 10700
-
Thailand
Novartis Investigative Site
-
Chiangmai, 50200
-
Thailand
Ukraine
Novartis Investigative Site
-
Dnepropetrovsk, 49102
-
Ukraine
Novartis Investigative Site
-
Dnipropetrovsk, 49100
-
Ukraine
Novartis Investigative Site
-
Lviv, 79031
-
Ukraine
Novartis Investigative Site
-
Sumy, 40005
-
Ukraine
United Kingdom
Novartis Investigative Site
-
Bournemouth, BH7 7DW
-
United Kingdom
Novartis Investigative Site
-
Brighton, BN2 5BE
-
United Kingdom
Novartis Investigative Site
-
Chelmsford, CM1 7ET
-
United Kingdom
Novartis Investigative Site
-
Cheltenham, GL53 7AN
-
United Kingdom
Novartis Investigative Site
-
Colchester, CO3 3NB
-
United Kingdom
Novartis Investigative Site
-
Cottingham, Hull, HU16 5JQ
-
United Kingdom
Novartis Investigative Site
-
Derby, DE22 3NE
-
United Kingdom
Novartis Investigative Site
-
Edmonton, N18 1QX
-
United Kingdom
Novartis Investigative Site
-
Guildford, GU2 7XX
-
United Kingdom
Novartis Investigative Site
-
Harrogate, HG2 7SX
-
United Kingdom
Novartis Investigative Site
-
Huddersfield, HD3 3EA
-
United Kingdom
Novartis Investigative Site
-
London, SW3 6JJ
-
United Kingdom
Novartis Investigative Site
-
Newcastle upon Tyne, NE7 7DN
-
United Kingdom
Novartis Investigative Site
-
Norwich, NR4 7UY
-
United Kingdom
Novartis Investigative Site
-
Nottingham, NG5 1PB
-
United Kingdom
Novartis Investigative Site
-
Oxford, OX3 7LJ
-
United Kingdom
Novartis Investigative Site
-
Poole, Dorset, BH15 2JB
-
United Kingdom
Novartis Investigative Site
-
Sheffield, S10 2SJ
-
United Kingdom
Novartis Investigative Site
-
Shrewsbury, SY3 8XQ
-
United Kingdom
Novartis Investigative Site
-
Sutton, SM2 5PT
-
United Kingdom
Novartis Investigative Site
-
Whitchurch, Cardiff, CF14 2TL
-
United Kingdom
Novartis Investigative Site
-
York, YO31 8HE
-
United Kingdom

Have a question?

Call 1-999-669-6682 or email [email protected]